Posts

FDA grants clearance to Gilead Sciences’ sNDA for Veklury

FDA grants clearance to Gilead Sciences’ sNDA for Veklury

Aug 26, 2023

The US Food and Drug Administration (FDA) has granted clearance to Gilead Scienc...

Signal: NHS whistle-blower policy questioned following Letby conviction

Signal: NHS whistle-blower policy questioned following ...

Aug 26, 2023

In light of the conviction of UK nurse Lucy Letby for murder, doctors are callin...

Five ways to build trust in patient data sharing

Five ways to build trust in patient data sharing

Aug 26, 2023

Patient data sharing among various stakeholders for research purposes forms the ...

Merck and AstraZeneca receive approval for Lynparza in Japan

Merck and AstraZeneca receive approval for Lynparza in ...

Aug 26, 2023

Merck (MSD) and AstraZeneca have received approval in Japan for Lynparza to trea...

FDA approves the first Tysabri biosimilar for MS and Crohn’s disease

FDA approves the first Tysabri biosimilar for MS and Cr...

Aug 26, 2023

The Sandoz biosimilar, Tyruko, was approved by the US FDA for all labelled indic...

Microbiome company Enterome plans $108m raise to fund Phase II cancer trials

Microbiome company Enterome plans $108m raise to fund P...

Aug 26, 2023

The latest fundraise will close in 2024, with plans for one Phase II trial to st...

AstraZeneca scores its second paediatric approval for Soliris in Japan

AstraZeneca scores its second paediatric approval for S...

Aug 26, 2023

Soliris is already approved to treat refractory generalised myasthenia gravis in...

Abortion policy in the spotlight, DeSantis’ importation showdown, and new price hike analysis

Abortion policy in the spotlight, DeSantis’ importation...

Aug 25, 2023

GOP candidates debated over just how far the party should go on national abortio...

STAT+: Pharmalittle: Mid-year price hikes for U.S. drugs reaches new heights; onetime biotech CEO Vivek Ramaswamy sparks debate at GOP debate

STAT+: Pharmalittle: Mid-year price hikes for U.S. drug...

Aug 25, 2023

Good morning, Pharmalittle readers. Reporter Andrew Joseph here filling in for E...

STAT+: Drugmakers already bet big on mRNA for cancer. Why is Biden going in, too?

STAT+: Drugmakers already bet big on mRNA for cancer. W...

Aug 25, 2023

Drugmakers already bet big on mRNA for cancer. So why is Biden's new health agen...

Krystal Cascetta, Lindsay Clancy, and the impossibility of being a mom in American medicine

Krystal Cascetta, Lindsay Clancy, and the impossibility...

Aug 25, 2023

Medical professionals often find it very difficult to seek medical care for them...

STAT+: Mid-year drug price hikes are back despite Inflation Reduction Act

STAT+: Mid-year drug price hikes are back despite Infla...

Aug 25, 2023

If last month's price hikes are any indication, the Medicare rebate provisions i...

Opinion: How to save the U.S. News & World Report Best Hospitals rankings

Opinion: How to save the U.S. News & World Report Best ...

Aug 25, 2023

To be useful to patient and providers, rating systems must move past monolithic ...

STAT+: What past blockbusters can tell us about future of Wegovy and other weight loss medicines

STAT+: What past blockbusters can tell us about future ...

Aug 25, 2023

We can’t know what the future will look like for weight loss drugs. But in medic...

Vivek Ramaswamy’s brashness made waves in the Republican debate. He did the same in biotech

Vivek Ramaswamy’s brashness made waves in the Republica...

Aug 25, 2023

Vivek Ramaswamy’s brashness made waves in the Republican debate — much as it did...

STAT+: Neuroscience startup Neumora files for IPO

STAT+: Neuroscience startup Neumora files for IPO

Aug 25, 2023

Neumora, a neuroscience startup founded by VC Arch Venture Partners, hopes to be...